Brazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma

dc.creatorDuarte, BKL
dc.creatorValente, I
dc.creatorVigorito, AC
dc.creatorAranha, FJP
dc.creatorOliveira-Duarte, G
dc.creatorMiranda, ECM
dc.creatorLorand-Metze, I
dc.creatorPagnano, KB
dc.creatorDelamain, M
dc.creatorMarques, JF
dc.creatorBrandalise, SR
dc.creatorNucci, M
dc.creatorDe Souza, CA
dc.date2009
dc.dateDEC
dc.date2014-11-15T02:51:54Z
dc.date2015-11-26T17:35:48Z
dc.date2014-11-15T02:51:54Z
dc.date2015-11-26T17:35:48Z
dc.date.accessioned2018-03-29T00:18:00Z
dc.date.available2018-03-29T00:18:00Z
dc.identifierClinical Lymphoma & Myeloma. Cig Media Group, Lp, v. 9, n. 6, n. 449, n. 454, 2009.
dc.identifier1557-9190
dc.identifierWOS:000272208300008
dc.identifier10.3816/CLM.2009.n.088
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/63225
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/63225
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/63225
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1285675
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionPurpose: We evaluate the effectiveness and toxicity of high-dose sequential chemotherapy (HDS) as salvage therapy in patients with advanced-stage Hodgkin lymphoma. Patients and Methods: We performed a retrospective analysis on 77 patients receiving HDS between 1998 and 2006. Patients enrolled were in disease progression or relapsed disease, or did not achieve a complete remission after first-line treatment. HDS consisted of the sequential administration of cyclophosphamide and granulocyte colony-stimulating factor with stem cell harvesting, followed by methotrexate plus vincristine and etoposide. Results: The majority of patients had stage III/IV (64%) and B symptoms (71.4%). Disease status improvement after HDS was observed in 24 of 57 patients (42%) previously in disease progression or relapse. HDS-related deaths occurred in 8 of 77 patients (10.4%). Four patients (5.2%) developed acute myeloid leukemia/myelodysplastic syndrome. Overall, disease-free and progression-free survival was 27%, 57%, and 25%, respectively. Conclusion: Despite the treatment-related mortality, HDS is feasible, with satisfactory response rates, even in patients with poor prognosis.
dc.description9
dc.description6
dc.description449
dc.description454
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.languageen
dc.publisherCig Media Group, Lp
dc.publisherDallas
dc.publisherEUA
dc.relationClinical Lymphoma & Myeloma
dc.relationClin. Lymphoma Myeloma
dc.rightsfechado
dc.sourceWeb of Science
dc.subjectAutologous stem cell transplantation
dc.subjectHigh-dose cyclophosphamide
dc.subjectEpstein-Barr virus
dc.subjectHodgkin's lymphoma
dc.subjectBone-marrow-transplantation
dc.subjectDisease-free Survival
dc.subjectEpstein-barr-virus
dc.subjectPrognostic Factors
dc.subjectSalvage Chemotherapy
dc.subjectRandomized-trial
dc.subjectBlood
dc.subjectChemoradiotherapy
dc.subjectCyclophosphamide
dc.subjectEtoposide
dc.titleBrazilian Experience Using High-Dose Sequential Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución